Search
Now showing items 1-6 of 6
HIV-1 diversity and the implementation of integrase strand-transfer inhibitors as part of combination antiretroviral therapy
(SAMA, 2020)
: The integrase (IN) strand-transfer inhibitor (InSTI)
dolutegravir (DTG) is now recommended by the World Health
Organization as part of salvage and/or first-line combination
antiretroviral therapy (cART).[1] DTG has a ...
Structural rearrangements maintain the Glycan Shield of an HIV-1 envelope trimer after the loss of a glycan
(Nature Research, 2018)
The HIV-1 envelope (Env) glycoprotein is the primary target of the humoral immune response and a
critical vaccine candidate. However, Env is densely glycosylated and thereby substantially protected
from neutralisation. ...
Structural comparison of diverse HIV-1 subtypes using molecular modelling and docking analyses of integrase inhibitors
(MPDI, 2020)
The process of viral integration into the host genome is an essential step of the HIV-1 life cycle. The viral integrase (IN) enzyme catalyzes integration. IN is an ideal therapeutic enzyme targeted by several drugs; ...
Characterizing the emergence and persistence of drug resistant mutations in HIV-1 subtype C infections using 454 ultra deep pyrosequencing
(BioMed Central -The Open Access Publisher, 2013)
BACKGROUND: The role of HIV-1 RNA in the emergence of resistance to antiretroviral therapies (ARTs) is well
documented while less is known about the role of historical viruses stored in the proviral DNA. The primary ...
Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations
(BMC, 2021)
The Integrase (IN) strand transfer inhibitor (INSTI), Dolutegravir (DTG), has been given the green light
to form part of first-line combination antiretroviral therapy (cART) by the World Health Organization (WHO). ...
Drug resistance mutations against protease, reverse transcriptase and integrase inhibitors in people living with HIV-1 receiving boosted protease inhibitors in South Africa
(Frontiers Media S.A., 2020)
The South African national combination antiretroviral therapy (cART) roll-out program started in 2006, with over 4.4 million people accessing treatment since it was first introduced. HIV-1 drug resistance can hamper the ...